Rigel Pharmaceuticals Inc (RIGL) stock analysis
Close on Nov 11, 2026Market cap $831.63MP/E 2.9Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Mixed11 of 30 checks passed
Rigel Pharmaceuticals passes 11 of the 30 checks behind our score; 14 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 3/6
- Growth
- 1/6
- Past performance
- 4/6
- Financial health
- 3/6
- Dividend
- 0/6
What stands out
Return on capital over 10%
Return on invested capital was 46.4%, above the 10% that usually covers the cost of capital.
Revenue growing 10%+ a year
Revenue grew 34.8% a year over the last three fiscal years.
Interest well covered
Operating income covers interest expense 18.2 times.
Low bankruptcy risk
The Altman Z-score is 4.98; above 3 is the safe zone and below 1.8 the distress zone.
What to watch
Guidance lowered
Rigel Pharmaceuticals lowered its 2026 Contract revenues outlook on Aug 4, 2026.
EV/EBITDA above its 5-year median
Rigel Pharmaceuticals's EV/EBITDA of 9.2 is above its 5-year median of 5.7.
Growing slower than the industry
Revenue grew 2.2% over the last twelve months; the Drugs median is 8.0%.
Gross margin slipping
Gross margin was 89.6% over the last twelve months, against 93.1% a year earlier.
Valuation3/6
P/E below its 5-year median
Rigel Pharmaceuticals's P/E of 2.9 is below its own 5-year median of 6.6.
P/E below the industry
Rigel Pharmaceuticals's P/E of 2.9 is below the Drugs median of 25.1.
EV/EBITDA above its 5-year median
Rigel Pharmaceuticals's EV/EBITDA of 9.2 is above its 5-year median of 5.7.
P/B below the industry
Rigel Pharmaceuticals's price-to-book of 1.87 is below the Drugs median of 2.29.
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.
Growth1/6
Revenue growing 10%+ a year
Revenue grew 34.8% a year over the last three fiscal years.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing slower than the industry
Revenue grew 2.2% over the last twelve months; the Drugs median is 8.0%.
Guidance lowered
Rigel Pharmaceuticals lowered its 2026 Contract revenues outlook on Aug 4, 2026.
Gross margin slipping
Gross margin was 89.6% over the last twelve months, against 93.1% a year earlier.
Past performance4/6
Return on equity
Needs positive equity and five years of results.
Return on capital over 10%
Return on invested capital was 46.4%, above the 10% that usually covers the cost of capital.
Return on equity above the industry
Rigel Pharmaceuticals's return on equity of 109% is above the Drugs median of -58.9%.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin above its 5-year average
Net margin was 107% over the last twelve months, against a 5-year average of 10.5%.
Net margin above the industry
Rigel Pharmaceuticals's net margin of 107% is above the Drugs median of -53.0%.
Financial health3/6
Debt level
Needs debt and equity figures.
Debt trend
Needs a balance sheet from five years ago with positive equity.
Debt coverage
Needs operating cash flow.
Interest well covered
Operating income covers interest expense 18.2 times.
Short-term assets cover short-term debts
Current assets are 2.39 times current liabilities.
Low bankruptcy risk
The Altman Z-score is 4.98; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
Rigel Pharmaceuticals has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itWe don't publish a fair value for Rigel Pharmaceuticals. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Own 5-year median 6.6
- Drugs median 25.1
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Medium risk
- Average value traded per day
- $11.37M
- Value traded per 1% price move
- $5.26M
Downside
High risk
- Typical loss in a bad month
- 26.3%
- Volatility (annualized)
- 56%
- Sharpe ratio, 1 year
- 0.44
- Beta to the S&P 500 (5Y)
- 1.07
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +64.1% | +34.8% | +22.1% | – | |
| Gross profit | +71.0% | +32.3% | +20.6% | – | |
| Operating income | +418.6% | – | – | – | |
| Net income | +1999.1% | – | – | – | |
| EPS, diluted | +1867.7% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -67.7% | 185.9% | |
| Return on assets | – | -23.1% | 108.3% | |
| Current ratio | 3.37 | 2.18 | 2.42 | |
| Interest coverage | – | -21.4× | 17.1× | |
| Inventory turnover | – | 0.6× | 2.2× | |
| Capex to revenue | 3.9% | 1.2% | – | |
| Diluted shares | 9M | 17M | 19M |
Cash use needs five years of cash flow figures
Rigel Pharmaceuticals does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 124.7% | 0.87× | 1.72× | 185.9% |
| FY2024 | 9.8% | 1.28× | -11.09× | -137.9% |
| FY2023 | -21.5% | 0.93× | -5.95× | 118.7% |
| FY2022 | -48.7% | 0.80× | 18.00× | -699.0% |
| FY2021 | -12.0% | 1.07× | 4.31× | -55.6% |
| FY2020 | -27.4% | 0.84× | 2.94× | -67.7% |
| FY2019 | -112.8% | 0.41× | 1.75× | -81.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$367.02M
- Cash generatingOperating cash flow above zero$75.66M
- Return on assets improvedROA up on the prior year14.9% → 223.8%
- Earnings backed by cashOperating cash flow above net income$75.66M vs $367.02M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.13 → 2.42
- No dilutionShare count did not rise18M → 19M
- Gross margin improvedGross margin up on the prior year89.60% → 93.33%
- More efficientAsset turnover rose1.53 → 1.79
See a number that looks wrong?